Immediate Impact
2 from Science/Nature 66 standout
Citing Papers
Targeting the tumour vasculature: from vessel destruction to promotion
2024 Standout
Global Prevalence of Prediabetes
2023 Standout
Works of Shingo Kuroda being referenced
Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study
2015
An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors
2014
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Shingo Kuroda | 213 | 124 | 76 | 132 | 27 | 436 | |
| Xiaotao Wang | 161 | 52 | 62 | 24 | 33 | 429 | |
| Jing Gao | 188 | 25 | 50 | 14 | 29 | 444 | |
| Guang Wang | 234 | 28 | 60 | 47 | 26 | 411 | |
| Qingfeng Yu | 201 | 47 | 37 | 68 | 36 | 417 | |
| JY Reginster | 122 | 81 | 96 | 72 | 22 | 448 | |
| S Miyamoto | 128 | 119 | 68 | 67 | 18 | 450 | |
| Simone Donati | 243 | 30 | 55 | 26 | 23 | 423 | |
| Yanyan He | 113 | 8 | 114 | 24 | 24 | 441 | |
| Satoshi Matsui | 152 | 28 | 54 | 8 | 30 | 423 | |
| Xue Yu | 91 | 129 | 17 | 13 | 21 | 447 |
All Works
Login with ORCID to disown or claim papers
Loading papers...